New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
10:07 EDTHIMX, T, TKR, MSCI, CRK, AMX, PHM, KBR, TU, SPR, NAV, BMRN, ACI, CST, ANROn The Fly: Analyst Downgrade Summary
Alpha Natural (ANR) downgraded to Hold from Buy at Jefferies... Arch Coal (ACI) downgraded to Hold from Buy at Jefferies... BioMarin (BMRN) downgraded to Neutral from Buy at Goldman... CST Brands (CST) downgraded to Neutral from Overweight at JPMorgan... KBR (KBR) downgraded to Neutral from Buy at Goldman... MSCI (MSCI) downgraded to Neutral from Buy at UBS... Navistar (NAV) downgraded to Neutral from Buy at UBS... PulteGroup (PHM) downgraded to Underweight from Equalweight at Barclays... Timken (TKR) downgraded to Hold from Buy at KeyBanc... Spirit AeroSystems (SPR) downgraded to Underperform from Neutral at Buckingham... America Movil (AMX) downgraded at BofA/Merrill... AT&T (T) downgraded to Neutral from Overweight at HSBC... TELUS (TU) downgraded to Equal Weight from Overweight at Morgan Stanley... Comstock Resources (CRK) downgraded to Accumulate from Buy at KLR Group... Himax Technologies (HIMX) downgraded to Underperform from Buy at BofA/Merrill.
News For ANR;ACI;BMRN;CST;KBR;MSCI;NAV;PHM;TKR;SPR;AMX;T;TU;CRK;HIMX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 26, 2015
12:30 EDTTAT&T may need to choose between dividend and credit rating, CTFN reports
AT&T, despite acquiring DirecTV, may have to choose between maintaining its credit rating and its dividend in a few years as web video displaces satellite, CTFN reports, citing two credit analysts and a senior executive. AT&T has reduced the pressure from high dividend payments after the DirecTV purchase, but "it could be back in the same situation within three years if DirecTV's cash flow isn't sustainable," according to Mark Stodden, VP and senior credit officer at Moody's. AT&T spokesperson said that any suggestion that it needs to reduce its dividend "ignores the facts," the report says. Reference Link
10:02 EDTSPRSpirit AeroSystems upgraded to Buy from Hold at Standpoint Research
Subscribe for More Information
August 25, 2015
13:00 EDTPHMToll Brothers lags market rebound after reporting Q3 results
Shares of luxury home builder Toll Brothers (TOL) are trading lower after reporting third quarter profit and revenue that were lower than last year's Q3 results. WHAT'S NEW: Toll Brothers this morning reported Q3 earnings per share of 36c, well below the 53c the company reported in the year-ago quarter. Revenue for the quarter of $1.03B and deliveries of 1,419 units declined 3% in dollars and 2% in units from the year-ago level, while impairments rose to $18M from $6M in the year-ago quarter. Analysts were expecting Toll Brothers to report Q3 EPS of 49c on revenue of $1.05B. The company said that the average price of homes delivered was $724,000, compared to $732,000 in 3Q14. Looking ahead, Toll Brothers forecast fourth quarter deliveries of 1,645-1,945 units priced between $780,000-$800,000. The company also lowered the top end of its 2015 home deliveries forecast, and now sees deliveries of 5,350-5,650 homes compared to its prior forecast of 5,300-5,900 homes. Separately, The Commerce Department reported new home sales for July were up 5.4% to an annual pace of 507,000, which fell within the range of expectations. WHAT'S NOTABLE: On quarterly earnings conference call, Toll Brothers said it still sees net income and gross margin growth in 2016. The company added that the housing recovery is built on a "very solid foundation." The steady acceleration the industry is experiencing bodes well for the health of housing market due to pent-up demand, increasing household formations and current industry-wide production, the company said. The home builder said that there is "significant room" for growth with increased profitability in fiscal year 2016 and beyond. Toll also said it sees further consolidation in the sector. OTHERS TO WATCH: Other companies in the home building space include Lennar Corporation (LEN) PulteGroup (PHM), Hovnanian Enterprises, (HOV) and Ryland Group (RYL). PRICE ACTION: Shares of Toll Brothers are down 0.5% to $37.87 amid a broader market advance.
09:55 EDTTKRTimken management to meet with CL King
Subscribe for More Information
06:25 EDTTAT&T to rebrand services in Mexico, WSJ reports
Subscribe for More Information
August 24, 2015
16:46 EDTACI, ANRPresident Obama announces new renewable energy commitments
Subscribe for More Information
16:00 EDTTOptions Update; August 24, 2015
Subscribe for More Information
13:54 EDTBMRNFly Watch: Sarepta upgraded ahead of FDA deadline on DMD drug
The 60-day FDA review period for Sarepta's (SRPT) rolling NDA submission for its Duchenne muscular dystrophy drug eteplirsen ends tomorrow, Tuesday, August 25. Piper Jaffray is among research firms taking a bullish stance on the stock ahead of tomorrow's deadline. BACKGROUND: Eteplirsen is an "exon skipping" treatment that attempts to bypass genetic mutations to allow improved functioning of the affected gene. On August 21, Sarepta announced that the FDA granted a rare pediatric disease designation for eteplirsen, in addition to its previous orphan designation and fast track status. Piper Jaffray's Edward Tenthoff noted today that the drug could see a February 2016 PDUFA date, potentially yielding "blockbuster sales" for the company. Importantly, BioMarin's (BMRN) drisapersen is slightly ahead of eteplirsen's approval process with a December 27 PDUFA date, posing a potential competitive risk for Sarepta. PDUFA dates are FDA deadlines for approving new drugs, normally coming within 6 or 10 months of an NDA acceptance depending on the drug's priority status. ANALYST TAKE: Tenthoff stated in note to investors this morning that he expects the Food and Drug Administration to accept the New Drug Application for Sarepta's eteplirsen at the end of its 60-day review period tomorrow. Additionally, Tenthoff sees a joint advisory committee for eteplirsen and the similar drisapersen from BioMarin on November 23-24. On May 19, Sarepta said it held pre-NDA meetings with the FDA, and Piper Jaffray said it believes the company has now met all of the agency's information requests. The analyst upgraded Sarepta to Overweight from Neutral and hiked his price target to $48 from $28 and now values eteplirsen at $1.3B, up from $919M previously. PRICE ACTION: Shares of Sarepta Therapeutics are up roughly 1% in intraday trading to $34.21. The stock jumped about 60% on May 20 after the company announced its mid-year NDA plans for eteplirsen. BioMarin shares, meanwhile, are down 2% to $123.59 this afternoon.
07:02 EDTBMRNMedivation to acquire worldwide rights to Talazoparib from BioMarin
Medivation (MDVN) and BioMarin Pharmaceutical (BMRN) have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib, a highly-potent, orally-available poly ADP ribose polymerase inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer. Under the agreement, Medivation will be responsible for all research, development, regulatory and commercialization activities for all indications on a global basis. Under the terms of the agreement, Medivation will pay BioMarin $410 million upfront, up to an additional $160 million upon the achievement of regulatory and sales-based milestones and mid-single digit royalties for talazoparib. At the closing of the transaction, Medivation will assume all financial obligations associated with the development and commercialization of talazoparib. The closing of the transaction is conditioned on the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is anticipated to close in 2015.
August 23, 2015
19:13 EDTTBT executive says Verizon, AT&T abusing landline duopoly, FT reports
In a Financial Times interview published Sunday, BT Group's (BT) Americas president Bas Burger said Verizon (VZ) and AT&T (T) are abusing their control over telephone and broadband lines to charge inappropriate access fees to companies like BT. "For a western world country it is the worst I've seen... There is not sufficient regulation to create competition: almost all access is being provided by two companies and they have divided the country among themselves," remarked Burger, adding that the two companies are also not required to fix network problems within any specific timeframe. Reference Link
August 21, 2015
09:38 EDTBMRNUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
06:23 EDTBMRNUBS sees 'meaningful' upside to BioMarin on positive Hemophilia data
Subscribe for More Information
August 20, 2015
08:02 EDTTFCC to hold a conference and workshop
2015 Supplier Diversity Conference & Workshop is being held at FCC Washington, D.C. offices on August 20 at 9:30 am. Webcast Link
August 19, 2015
16:06 EDTBMRNBioMarin receives rare pediatric disease designation from FDA for drisapersen
Subscribe for More Information
10:20 EDTTBig telecom firms put M&A on hold, CTFN reports
Subscribe for More Information
10:00 EDTNAVOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Biocept (BIOC) initiated with a Buy at H.C. Wainwright... C.H. Robinson (CHRW) initiated with a Buy at Evercore ISI... Chipotle (CMG) initiated with a Hold at Maxim... Con-way (CNW) initiated with a Buy at Evercore ISI... Dermira (DERM) initiated with an Outperform at Cowen... Expeditors (EXPD) initiated with a Hold at Evercore ISI... Fleetmatics (FLTX) initiated with an In-Line at Imperial Capital... Frontier Communications (FTR) initiated with an Overweight at Stephens... Gevo (GEVO) initiated with a Buy at Rodman & Renshaw... International Game (IGT) initiated with a Sell at Goldman... Knight Transportation (KNX) initiated with a Buy at Evercore ISI... Logitech (LOGI) initiated with a Buy at Rosenblatt... Navistar (NAV) initiated with a Neutral at Macquarie... Panera Bread (PNRA) initiated with a Hold at Maxim... Scientific Games (SGMS) initiated with a Sell at Goldman... Swift Transport (SWFT) initiated with a Hold at Evercore ISI... Tribune Media (TRCO) initiated with an Equal Weight at Morgan Stanley... WEX Inc. (WEX) initiated with an Equal Weight at Barclays... Zoe's Kitchen (ZOES) initiated with a Buy at Maxim.
09:17 EDTBMRN'Female Viagra' approval seen as positive for Sarepta, BioMarin
The FDA's approval of the world's first drug designed to boost a woman's sexual desire is seen as boding well for companies awaiting critical decisions by the agency. FEMALE VIAGRA: The Food and Drug Administration yesterday approved flibanserin to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug, which will be sold under the name "Addyi" and is commonly referred to as the "female Viagra," is the first FDA-approved treatment for sexual desire disorders in men or women, the agency prominently stated in its press release. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, the FDA explained. Addyi was approved with a risk evaluation and mitigation strategy as well as a Boxed Warning given the risk of severe hypotension and syncope in patients who drink alcohol during treatment. The drug is made by privately held Sprout Pharmaceuticals. ANALYST REACTION: Addyi's approval is "another sign of flexibility" by the FDA, especially for first-in-class therapies, Roth Capital analyst Debjit Chattopadhyay writes this morning in a note to investors. This bodes well for the approval of eteplirsen, drisapersen and Translarna, the analyst contends. Eteplirsen, designed by Sarepta Therapeutics (SRPT), and drisapersen, designed by BioMarin (BMRN), are experimental drugs being developed to treat Duchenne muscular dystrophy. Translarna, designed by PTC Therapeutics (PTCT), is already being sold in Europe as a treatment for DMD and is awaiting approval from the FDA. Duchenne muscular dystrophy is a form of muscular dystrophy affecting around 1 in 3,600 boys, which results in muscle degeneration and premature death. SAVING LIVES: While female sexual dysfunction is a clinical problem, eteplirsen is designed to save lives, Chattopadhyay points out. He has a Buy rating on Sarepta and noted his price target of $45 assumes accelerated approval for eteplirsen in the first quarter of 2016. Shares of the Massachusetts-based biopharmaceutical company closed yesterday at $35.69.
08:29 EDTBMRNFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
08:22 EDTTSprint traffic levels increasing, says Pacific Crest
Subscribe for More Information
06:31 EDTNAVNavistar initiated with a Neutral at Macquarie
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use